STARD13 (46H23.2) as a Potential Drug Target and Biomarker (G90627)

Target Name: STARD13

NCBI ID: G90627

STARD13

STARD13 (46H23.2) as a Potential Drug Target and Biomarker

Abstract:

Stard13 (46H23.2) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and expression pattern in various tissues have piqued the interest of researchers, and studies have suggested that it may play a critical role in the development and progression of various diseases. In this article, we will explore the biology and potential therapeutic applications of STARD13 (46H23.2).

Introduction:

Stard13 (46H23.2) is a non-coding RNA molecule that has been identified in various cellular processes. Its unique structure, consisting of 23 exons and a splice leader region, has led to its complexity and the possibility of its involvement in various biological processes. Several studies have suggested that STARD13 (46H23.2) may be a drug target and biomarker, and its potential therapeutic applications are being investigated.

Structure and Expression:

The structure of STARD13 (46H23.2) is unique, as it consists of two main regions: the first region includes a 5' splice leader region and the second region includes a 3' non-coding RNA molecule. The 5' splice leader region is responsible for guiding the correct splicing of exons and is a critical region for the formation of functional RNA molecules. The 3' non-coding RNA molecule is thought to play a role in the regulation of various cellular processes.

Expression:

STARD13 (46H23.2) is expressed in various tissues, including brain, heart, and muscle. Its expression pattern is highly variable, with increased expression in tissues that are susceptible to certain diseases. This suggests that STARD13 (46H23.2) may be involved in the development and progression of these diseases.

Drug Target Potential:

The unique structure of STARD13 (46H23.2) and its expression pattern in various tissues make it an attractive drug target. Studies have shown that STARD13 (46H23.2) is involved in various cellular processes, including cell growth, apoptosis, and inflammation. Its expression is also associated with the development of certain diseases, such as cancer and neurodegenerative diseases.

Biomarker Potential:

STARD13 (46H23.2) may also be used as a biomarker for various diseases. Its expression pattern is affected by various factors, including genetic and environmental factors. This makes it a potential candidate for use as a diagnostic biomarker for diseases that are dependent on the regulation of STARD13 (46H23.2) expression.

Conclusion:

In conclusion, STARD13 (46H23.2) is a non-coding RNA molecule that has unique structure and expression pattern. Its potential as a drug target and biomarker has generated significant interest among researchers. Further studies are needed to fully understand its role in various biological processes and its potential therapeutic applications.

FAQs:

Q1: What is STARD13 (46H23.2)?
A1: STARD13 (46H23.2) is a non-coding RNA molecule that has been identified in various cellular processes.

Q2: What is the function of STARD13 (46H23.2)?
A2: The function of STARD13 (46H23.2) is not yet fully understood, but it is thought to play a role in various cellular processes, including

Protein Name: StAR Related Lipid Transfer Domain Containing 13

Functions: GTPase-activating protein for RhoA, and perhaps for Cdc42. May be involved in regulation of cytoskeletal reorganization, cell proliferation and cell motility. Acts a tumor suppressor in hepatocellular carcinoma cells

The "STARD13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STARD13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets